BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8103569)

  • 1. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
    Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
    Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the schizophrenic patients' level of information about their disease and their treatment?
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000 Oct; 26 Spec No 1():15-22. PubMed ID: 11294058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
    Hornung WP; Schonauer K; Feldmann R; Mönking HS
    Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What information do patients with schizophrenia have about their illness and treatment?].
    Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
    Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
    Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
    Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
    Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
    Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
    Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M; Scheel T; Eich FX
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug compliance and health locus of control in schizophrenia].
    Combes C; Feral F
    Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Compliance in therapy of schizophrenic patients with neuroleptics--an overview].
    Mayer C; Soyka M
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):217-22. PubMed ID: 1353747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychological effects of previous treatment experiences with neuroleptics].
    Bossert S; Dose M; Emrich HM; Garcia D; Junker M; Raptis K; Weber MM
    Nervenarzt; 1990 May; 61(5):301-5. PubMed ID: 1972785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication.
    Gray R; Rofail D; Allen J; Newey T
    J Adv Nurs; 2005 Oct; 52(1):31-7. PubMed ID: 16149978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.